株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

大うつ病性障害 - 日本における医薬品の予測と市場分析

Major Depressive Disorder - Japan Drug Forecast and Market Assessment to 2025

発行 GlobalData 商品コード 305472
出版日 ページ情報 英文 326 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.40円で換算しております。
Back to Top
大うつ病性障害 - 日本における医薬品の予測と市場分析 Major Depressive Disorder - Japan Drug Forecast and Market Assessment to 2025
出版日: 2016年10月05日 ページ情報: 英文 326 Pages
概要

当レポートでは、日本における大うつ病性障害の治療薬市場について調査分析し、疾患の概要とガイドライン、競合情勢、主要薬剤の詳細情報(製品説明、安全性、有効性)、SWOT分析、売上高予測、影響分析(動向、促進要因・抑制要因)などをまとめ、お届けいたします。

第1章 目次

第2章 イントロダクション

第3章 疾患の概要

  • 病因・病態生理
    • 病因
    • 病態生理
  • 分類
  • 症状およびサブタイプ
  • 予後
  • QOL

第4章 疾病の管理

  • 症状と治療の概要
  • 日本

第5章 競合評価

  • 概要
  • 製品プロファイル:主要ブランド、選択的セロトニン再取り込み阻害剤
  • 製品プロファイル:主要ブランド、セロトニン-ノルアドレナリン再取り込み阻害剤
  • 製品プロファイル:主要ブランド、その他の抗うつ薬
  • 製品プロファイル:主要ブランド、抗精神薬
  • その他の治療薬クラス

第6章 機会とアンメットニーズ

  • 概要
  • より効果的な薬物療法
  • より良好な副作用プロファイル
  • 抗うつ効果の迅速な発現
  • 個別化医療のアプローチ

第7章 パイプライン評価

  • 概要
  • 臨床開発中の有望な薬剤
  • その他開発中の薬剤

第8章 市場の見通し

  • 日本

第9章 付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHC377CFR

Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. It is characterized by single or recurrent major depressive episodes (MDEs), where patients can typically experience periods of depressed mood, loss of energy, abnormal cognition, anxiety and suicidal ideation. Similar to other neuropsychiatric disorders, MDD has a multifaceted and varied etiology, and remains poorly understood. The MDD market is crowded and competitive, with more than 30 products available for the treatment of patients, the majority of which are now available as inexpensive generics. The MDD market is therefore in a dynamic phase where patent expiries for historically top-selling products such as Eli Lilly's Cymbalta and Otsuka/BMS' Abilify have occurred, and recent launches of Lundbeck/Takeda's Trintellix and Otsuka/Lundbeck's Rexulti will be a significant driver of growth in the 7MM. Growth in the MDD market is also expected to be driven by the potential introduction of six promising late-stage pipeline products into the market during the forecast period, all of which are directed towards treatment-resistant patients, a significant unmet need.

GlobalData estimated that MDD drug sales in Japan during 2015 reached $315.0m, making it the second largest single market in the 7MM. GlobalData estimates that the Japanese MDD market will be turbulent during the forecast period with important patent losses occurring, such as Otsuka/BMS' Abilify, Eli Lilly's Cymbalta, and Lundbeck/Allergan's Lexapro. Effexor will see the highest growth rate of any drug in the Japanese MDD market over the 10-year forecast.

Scope

  • Overview of MDD including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in Japan including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in Japan from 2015-2025.
  • Analysis of the impact of key events as well the drivers and restraints affecting Japan MDD market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for MDD.
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2015-2025 in Japan.

Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 6
  • 1.2 List of Figures 10

2 Introduction 11

  • 2.1 Related Reports 11
  • 2.2 Upcoming Related Reports 12

3 Disease Overview 13

  • 3.1 Etiology and Pathophysiology 13
    • 3.1.1 Etiology 13
    • 3.1.2 Pathophysiology 14
  • 3.2 Classification 17
  • 3.3 Symptoms and Subtypes of Major Depressive Disorder 19
  • 3.4 Prognosis 20
  • 3.5 Quality of Life 20

4 Disease Management 21

  • 4.1 Diagnosis and Treatment Overview 21
    • 4.1.1 Diagnosis 21
    • 4.1.2 Treatment Guidelines 22
    • 4.1.3 Clinical Practice 24
  • 4.2 Japan 28

5 Competitive Assessment 31

  • 5.1 Overview 31
  • 5.2 Selective Serotonin Reuptake Inhibitors 33
    • 5.2.1 Lexapro (Escitalopram) 33
    • 5.2.2 Viibryd (Vilazodone) 41
    • 5.2.3 Other Selective Serotonin Reuptake Inhibitors 45
  • 5.3 Serotonin-Norepinephrine Reuptake Inhibitors 59
    • 5.3.1 Cymbalta (Duloxetine) 59
    • 5.3.2 Effexor (Venlafaxine) 67
    • 5.3.3 Fetzima (Levomilnacipran) 74
    • 5.3.4 Savella (Milnacipran) 80
    • 5.3.5 Pristiq (Desvenlafaxine) 85
  • 5.4 Multimodal Antidepressants 90
    • 5.4.1 Trintellix (Vortioxetine) 90
  • 5.5 Other Antidepressants 99
    • 5.5.1 Bupropion 99
    • 5.5.2 Symbyax (Olanzapine/Fluoxetine) 105
    • 5.5.3 Mirtazapine 110
    • 5.5.4 Monoamine Oxidase Inhibitors 115
    • 5.5.5 Tricyclic Antidepressants 119
  • 5.6 Antipsychotics 123
    • 5.6.1 Abilify (Aripiprazole) 123
    • 5.6.2 Seroquel XR (Quetiapine XR) 130
    • 5.6.3 Rexulti (Brexpiprazole) 135
  • 5.7 Other Therapeutic Classes 141

6 Unmet Need and Opportunity 142

  • 6.1 Overview 142
  • 6.2 New Therapies with Better Efficacy 144
    • 6.2.1 Unmet Need 144
    • 6.2.2 Gap Analysis 146
    • 6.2.3 Opportunity 147
  • 6.3 Improved Safety Profiles 148
    • 6.3.1 Unmet Need 148
    • 6.3.2 Gap Analysis 150
    • 6.3.3 Opportunity 151
  • 6.4 Rapid Onset of Action 153
    • 6.4.1 Unmet Need 153
    • 6.4.2 Gap Analysis 154
    • 6.4.3 Opportunity 156
  • 6.5 Personalized Treatment Approach 157
    • 6.5.1 Unmet Need 157
    • 6.5.2 Gap Analysis 158
    • 6.5.3 Opportunity 159
  • 6.6 Manage Patient Outcome Expectations 161
    • 6.6.1 Unmet Need 161
    • 6.6.2 Gap Analysis 163
    • 6.6.3 Opportunity 164

7 Pipeline Assessment 166

  • 7.1 Overview 166
  • 7.2 Clinical Trial Mapping 166
    • 7.2.1 Clinical Trials by Class of Therapy 166
  • 7.3 Promising Drugs in Clinical Development 167
    • 7.3.1 ALKS-5461 171
    • 7.3.2 Vraylar (Cariprazine) 180
    • 7.3.3 ASC-01 187
    • 7.3.4 AXS-05 190
    • 7.3.5 Esketamine 197
    • 7.3.6 Rapastinel (GLYX-13) 205
    • 7.3.7 Strada (MSI-195) 213
    • 7.3.8 Viotra (Tramadol) 219
  • 7.4 Promising Drugs in Early-Stage Development 226
    • 7.4.1 CGP3466B 226
    • 7.4.2 NSI-189 227
  • 7.5 Other Drugs in Development 228

8 Market Outlook 230

  • 8.1 Japan 230
    • 8.1.1 Forecast 230
    • 8.1.2 Key Events 232
    • 8.1.3 Drivers and Barriers 233

9 Appendix 234

  • 9.1 Bibliography 234
  • 9.2 Abbreviations 280
  • 9.3 Methodology 291
  • 9.4 Forecasting Methodology 291
    • 9.4.1 Diagnosed NSCLC Patients 291
    • 9.4.2 Percent Drug-Treated Patients 292
    • 9.4.3 Drugs Included in Each Therapeutic Class 292
    • 9.4.4 Launch and Patent Expiry Dates 295
    • 9.4.5 General Pricing Assumptions 297
    • 9.4.6 Individual Drug Assumptions 299
    • 9.4.7 Generic Erosion 313
    • 9.4.8 Pricing of Pipeline Agents 313
  • 9.5 Primary Research - KOLs 318
    • 9.5.1 KOLs 318
  • 9.6 About the Authors 322
    • 9.6.1 Analyst 322
    • 9.6.2 Therapy Area Director 322
    • 9.6.3 Epidemiologist 323
    • 9.6.4 Global Head of Healthcare 323
  • 9.7 About GlobalData 325
  • 9.8 Disclaimer 325

List of Tables

  • Table 1: Classification and Criteria of MDD (DSM-IV) and MDE (ICD-10) 18
  • Table 2: Subtypes of Major Depressive Disorder 19
  • Table 3: Severity of Depressive Episodes According to ICD-10 and DSM-IV Diagnostic Criteria 22
  • Table 4: Treatment Guidelines for Major Depressive Disorder 23
  • Table 5: Most-Prescribed Drugs for MDD by Class in the 7MM, 2015 24
  • Table 6: Country Profile - Japan 30
  • Table 7: Leading Treatments for MDD, 2016 33
  • Table 8: Product Profile - Lexapro 37
  • Table 9: Lexapro/Cipralex SWOT Analysis, 2016 40
  • Table 10: Product Profile - Viibryd 43
  • Table 11: Summary of Efficacy Results for the Primary Endpoint in Viibryd Clinical Trials 44
  • Table 12: Viibryd SWOT Analysis, 2016 45
  • Table 13: Summary of SSRIs, 2016 49
  • Table 14: SSRIs SWOT Analysis, 2016 59
  • Table 15: Product Profile - Cymbalta 64
  • Table 16: Cymbalta SWOT Analysis, 2016 66
  • Table 17: Product Profile - Effexor 71
  • Table 18: Effexor SWOT Analysis, 2016 73
  • Table 19: Product Profile - Fetzima 77
  • Table 20: Fetzima SWOT Analysis, 2016 79
  • Table 21: Product Profile - Savella 82
  • Table 22: Savella SWOT Analysis, 2016 84
  • Table 23: Product Profile - Pristiq 87
  • Table 24: Pristiq SWOT Analysis, 2016 89
  • Table 25: Product Profile - Trintellix 96
  • Table 26: Trintellix SWOT Analysis, 2016 98
  • Table 27: Product Profile - Bupropion 102
  • Table 28: Bupropion SWOT Analysis, 2016 104
  • Table 29: Product Profile - Symbyax 107
  • Table 30: Symbyax SWOT Analysis, 2016 109
  • Table 31: Product Profile - Mirtazapine 113
  • Table 32: Mirtazapine SWOT Analysis, 2016 115
  • Table 33: MAOIs SWOT Analysis, 2016 119
  • Table 34: TCAs SWOT Analysis, 2016 123
  • Table 35: Product Profile - Abilify 127
  • Table 36: Abilify SWOT Analysis, 2016 129
  • Table 37: Product Profile - Seroquel XR 132
  • Table 38: Seroquel XR SWOT Analysis, 2016 134
  • Table 39: Product Profile - Rexulti 138
  • Table 40: Rexulti SWOT Analysis, 2016 140
  • Table 41: Summary of Minor Therapeutic Classes in MDD, 2016 141
  • Table 42: Unmet Needs and Opportunities in MDD 143
  • Table 43: Promising Drugs in Clinical Development for MDD, 2016 168
  • Table 44: Comparison of Drugs in Development for MDD, 2016 170
  • Table 45: Product Profile - ALKS-5461 175
  • Table 46: SWOT Analysis - ALKS-5461, 2016 179
  • Table 47: Product Profile - Vraylar 183
  • Table 48: SWOT Analysis - Vraylar, 2016 186
  • Table 49: Product Profile - ASC-01 188
  • Table 50: SWOT Analysis - ASC-01, 2016 190
  • Table 51: Product Profile - AXS-05 194
  • Table 52: SWOT Analysis - AXS-05, 2016 196
  • Table 53: Product Profile - Esketamine 201
  • Table 54: SWOT Analysis - Esketamine, 2016 204
  • Table 55: Product Profile - Rapastinel 209
  • Table 56: SWOT Analysis - Rapastinel, 2016 212
  • Table 57: Product Profile - Strada 217
  • Table 58: SWOT Analysis - Strada, 2016 219
  • Table 59: Product Profile - Viotra 222
  • Table 60: SWOT Analysis - Viotra, 2015 225
  • Table 61: Drugs in Development, 2016 229
  • Table 62: Key Events Impacting Sales for MDD Therapies in Japan, 2015-2025 232
  • Table 63: MDD Market - Drivers and Barriers in Japan, 2015-2025 233
  • Table 64: Key Launch Dates - Part I 295
  • Table 65: Key Launch Dates - Part II 296
  • Table 66: Key Patent Expiries 297

Table 67 Average Body Weight and Surface Area Across the 8MM 298

  • Table 68: Average Cost of Therapy of Alimta in the 8MM 300
  • Table 69: Average Cost of Therapy of Alecensa in the 8MM 301
  • Table 70: Average Cost of Therapy of Avastin 302
  • Table 71: Average Cost of Therapy of Cyramza 302
  • Table 72: Average Cost of Therapy of Gilotrif 303
  • Table 73: Average Cost of Therapy of Iressa 304
  • Table 74: Average Cost of Therapy of Portrazza 305
  • Table 75: Average Cost of Therapy of Tagrisso 306
  • Table 76: Average Cost of Therapy of Tarceva 307
  • Table 77: Average Cost of Therapy of Vargatef 307
  • Table 78: Average Cost of Therapy of Xalkori 308
  • Table 79: Average Cost of Therapy of Zykadia 309
  • Table 80: Average Cost of Therapy of Keytruda 310
  • Table 81: Average Cost of Therapy of Opdivo 311
  • Table 82: Average Cost of Therapy of Tecentriq 312
  • Table 83: Average Cost of Therapy of Conmana 313
  • Table 84: High-Prescribing Physicians Surveyed by Country 321

List of Figures

  • Figure 1: Overview of Targets of Antidepressant Action on Noradrenergic and Serotonergic Neurons 17
  • Figure 2: Disease Management Model for Major Depressive Disorder 25
  • Figure 3: Major Depressive Disorder Treatment Algorithm 27
  • Figure 4: MDD Therapeutics - Phase II and III Clinical Trials in the 7MM, 2016 167
  • Figure 5: MDD Phase II/Phase III Pipeline, 2016 169
  • Figure 6: Competitive Assessment of Late-Stage Pipeline Agents in MDD, 2015-2025 171
  • Figure 7: Clinical and Commercial Positioning of ALKS-5461 178
  • Figure 8: Clinical and Commercial Positioning of Vraylar 185
  • Figure 9: Clinical and Commercial Positioning of ASC-01 189
  • Figure 10: Clinical and Commercial Positioning of AXS-05 195
  • Figure 11: Clinical and Commercial Positioning of Esketamine 203
  • Figure 12: Clinical and Commercial Positioning of Rapastinel 211
  • Figure 13: Clinical and Commercial Positioning of Strada 218
  • Figure 14: Clinical and Commercial Positioning of Viotra 224
  • Figure 15: Japan Sales by Drug Class for MDD Therapies, 2015 and 2025 231
  • Figure 16: Japan Sales by Drug Class for MDD Therapies, 2015-2025 232
Back to Top